Clinical development know-howFrench biopharma company Pharnext has appointed René Goedkoop as its new Chief Medical Officer. He joins the neurodegenerative disease specialist from Swiss Shogu Consulting SarL. more ➔
Immunotherapy pioneerMatthias Schroff, erstwhile CEO of Mologen, has taken over the helm of immunotherapy developer Vaximm AG. The Swiss-German company appointed him Chief Executive Officer in early September. more ➔
Overseas chiefSwedish clinical-stage biopharmaceutical company Aprea AB has named Christian Schade President and Chief Executive Officer. Before joining Aprea, Schade was CEO of US antiviral developer Novira Therapeutics, … more ➔
Vaccine proBrussels-based vaccine developer Univac has appointed a new CEO. In March, Stefano Malvolti joined Univac from Gavi, the Vaccine Alliance, where he was responsible for rolling out the vaccine development … more ➔
Pharma execFaron Pharmaceuticals has someone new to oversee its drug development strategy. In early May, the Turku-based clinical stage biopharma company appointed Matti Karvonen as its new Medical Director. … more ➔
Dab hand at financesUS- and UK-based genomics company Inivata has appointed Timothy Shannon as Chief Financial Officer. Shannon joins Inivata fom Baxano Surgical, where he held the position of CFO and treasurer. more ➔
Keeping an eye on monitoringPhilippe Dro is taking over the helm of NeMoDevices AG, a Switzerland-based developer in the innovative monitoring of brain blood flow and oxygen levels. The previous CEO Michael Oberle will serve as … more ➔
Well-versed in regulationSwedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer. more ➔
Trading upEduardo Bravo takes over as President of the Board of Directors of European Biopharmaceutical Enterprises (EBE). Bravo is CEO of Belgian stem cell-based drug developer TiGenix NV. more ➔
Neurological disorder specialistUwe Meya is taking over as Chief Medical Officer at Barcelona-based orphan drug developer Minoryx Therapeutics. Meya will advance the clinical development of Minoryx lead candidate MIN-102 for adrenoleukodystrophy. … more ➔
